Francis Senecal is an Oncology physician affiliated with Northwest Medical Specialties. OpenAlex indexes 30 publications with 2,875 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1624 S I St
Suite 305
Tacoma, WA 984055016
Telephone
253-383-3366Registry record last updated 17 Jul 2012.
Clinical trials
- Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo
Sponsor: South Sound Care Foundation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
51.2%Other antiemetics46.2%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist4.9%Palonosetron hcl77%Ondansetron hydrochloride22%Ondansetron Odt1%Part D + Part B<11 patients+ 2 more classes in this area
Cancer & immunology
21.3%PD-1 inhibitor18.3%Nivolumab100%Part B, office-administered≥12 patientsAromatase Inhibitor2.1%Anastrozole73%Letrozole18%Exemestane10%Part D≥107 patients+ 3 more classes in this area
Musculoskeletal
13.8%RANK Ligand Inhibitor13.3%Denosumab100%Part B, office-administered≥16 patientsBisphosphonate0.5%Zoledronic acid100%Part B, office-administered≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations
Journal of Clinical Oncology
2022 - P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
Journal of Thoracic Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
William Hirota, MD
Northwest Medical Specialties
Jorge Chaves, MD
Northwest Medical Specialties
Andrea Veatch, MD
Northwest Medical Specialties
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”